Loading clinical trials...

Endometrial Receptivity After GnRH Agonist Triggering | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Endometrial Receptivity After GnRH Agonist Triggering

Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation

NCT01500863•IVI Madrid

Summary

Conventional luteal phase support after human chorionic gonadotrophin (hCG) triggering in women undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) provides adequate pregnancy rates and live birth rates, but Ovarian hyperstimulation syndrome (OHSS) still occurs in 1-3% of the patients. If gonadotropin-releasing hormone agonist (GnRHa) are used instead of hCG, OHSS does not occur, but clinical results are somehow diminished. By testing different luteal support protocols on women undergoing GnRHa triggering, the investigators aim to find out which protocol resembles the most the gene expression profile observed after hCG triggering and conventional luteal phase support, in order to choose it as the most adequate in terms of endometrium receptivity and safety (OHSS incidence).

Eligibility

Age

18 - 35 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy oocyte donor women
•Aged 18-35 years
•With a menstrual cycle length of 26-35 days
•Normal ultrasound scan of uterus and ovaries
•Normal basal hormones
•No contraindication for controlled ovarian stimulation (COS)
•Willing to participate in the study and providing written informed consent.

Exclusion Criteria

•Subjects with current or previous history of an endocrine abnormality
•Subjects with an abnormal outcome of blood biochemistry or hematology
•Subjects with an abnormal cervical smear
•Subjects with a chronic disease
•Subjects with any relevant ovarian-, tubal- or uterine-pathology that could interfere with the COS treatment
•Pregnancy
•Subjects who had a previous history of ovarian hyperresponse or ovarian hyperstimulation syndrome (OHSS), polycystic ovary syndrome (PCOS) or a basal antral follicle count (AFC) of more than 20 on ultrasound (11 mm, both ovaries combined) .
•Previous low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to insufficient ovarian response or less than 6 oocytes obtained).
•A history of recurrent miscarriage,
•Smoking more than 10 cigarettes per day.
+1 more criteria

Locations (1)

Instituto Valenciano de Infertilidad

Madrid, Madrid, Spain

Key Dates

Start Date

November 1, 2011

Primary Completion Date

May 1, 2012

Last Updated

October 26, 2016

Enrollment

ACTUAL participants

Conditions

Ovarian Hyperstimulation Syndrome

Interventions

hCG

DRUG

triptorelin

DRUG

Triptorelin, estradiol valerate, micronized vaginal progesterone

DRUG

triptorelin, hCG

DRUG

triptorelin, hCG

DRUG

triptorelin, recombinant LH

DRUG

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

NCT05588635

Ovarian Hyperstimulation SyndromeFrozen-thawed Embryo Transfers

View study

UNKNOWNNA

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

NCT05198128

Ovarian Hyperstimulation Syndrome

View study

COMPLETEDPHASE2

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 26, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Endometrial Receptivity After GnRH Agonist Triggering

Inclusion Criteria

Exclusion Criteria

Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement Therapy

Ovarian Hyperstimulation Syndrome Using Calcium Infusion

Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes

Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)